Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.77 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL2085067 | 1.00 | TSHR (0.77) | TSHRTP53LMNAFFAR3LCK | |
| Cadaverine Tartrate SCHEMBL3972251 | 1.00 | TSHR (0.77) | TSHRTP53LMNAFFAR3LCK | |
| Cadaverine Tartrate SCHEMBL10319920 | 0.96 | TSHR (0.71) | TSHRTP53LMNAFFAR3LCK | |
| Cadaverine Tartrate SCHEMBL28136011 | 0.92 | TSHR (0.77) | TSHRTP53LMNAFFAR3LCK | |
| Cadaverine Tartrate SCHEMBL305065 | 0.92 | TSHR (0.77) | TSHRTP53LMNAFFAR3LCK | |
| Cadaverine Tartrate SCHEMBL11052134 | 0.89 | TSHR (0.71) | TSHRTP53LMNAFFAR3LCK | |
| Cadaverine Tartrate SCHEMBL42202 | 0.89 | TSHR (0.71) | TSHRTP53FFAR3LCKFYN | |
| Cadaverine Tartrate SCHEMBL28125338 | 0.89 | TSHR (0.71) | TSHRTP53LMNAFFAR3LCK | |
| Cadaverine Tartrate SCHEMBL11877140 | 0.89 | TSHR (0.71) | TSHRTP53LMNAFFAR3LCK | |
| Cadaverine Tartrate SCHEMBL4778934 | 0.88 | TSHR (0.83) | TSHRTP53LMNAFFAR3LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507838-B2 | Process for the preparation of Z-5-carboxymethylene-1,3-dioxolan-4-ones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-24 | — | — | US | claimed |
| EP-1784395-A1 | PROCESS FOR THE PREPARATION OF Z-5-CARBOXYMETHYLENE-1,3-DIOXOLAN-4-ONES | Bristol-Myers Squibb Company (US) | 2007-05-16 | — | — | EP | claimed |
| WO-2006028733-A1 | PROCESS FOR THE PREPARATION OF Z-5-CARBOXYMETHYLENE-1,3-DIOXOLAN-4-ONES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-03-16 | — | — | WO | claimed |
| US-20060047129-A1 | Process for the preparation of Z-5-carboxymethylene-1,3-dioxolan-4-ones | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-02 | — | — | US | claimed |
| US-7507838-B2 | Process for the preparation of Z-5-carboxymethylene-1,3-dioxolan-4-ones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1784395-A1 | PROCESS FOR THE PREPARATION OF Z-5-CARBOXYMETHYLENE-1,3-DIOXOLAN-4-ONES | Bristol-Myers Squibb Company (US) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006028733-A1 | PROCESS FOR THE PREPARATION OF Z-5-CARBOXYMETHYLENE-1,3-DIOXOLAN-4-ONES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060047129-A1 | Process for the preparation of Z-5-carboxymethylene-1,3-dioxolan-4-ones | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060047129-A1 | Process for the preparation of Z-5-carboxymethylene-1,3-dioxolan-4-ones | TKT, KTN1, TET1 | TSHR 4343/4885TP53 2699/4885LMNA 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.